Identification of Mechanoreceptor Piezo Ion Channels in Lymphatic Vessels Opens Path for Precision Treatment of Lymphedema and Cancer Metastasis
Background
The lymphatic system, a core axis of the human circulatory system, acts as a drainage network that recovers excess fluid within tissues and transports immune cells. While lymphatic biomechanics research was long overshadowed by vascular studies, it has recently entered a new era with the identification of cellular-level physical sensing mechanisms. Since lymph flows without a powerful pump like the heart, relying instead on surrounding muscle contractions and interstitial pressure gradients, lymphatic endothelial cells are constantly exposed to changing fluid shear stress and interstitial fluid pressure.
Previous studies have mainly focused on biochemical ligand signaling, including vascular endothelial growth factor-C (VEGF-C). However, chemical stimuli alone could not fully explain how lymphatic vessels perceive flow direction, form valves, or remodel networks. The specific molecular pathways by which mechanoreceptors convert physical stimuli into electrochemical signals in vivo remained shrouded in mystery. This lack of molecular targets for controlling physical microenvironmental changes has been a hurdle in treating diseases such as lymphedema, where limbs swell due to fluid retention, and cancer metastasis via lymphatic vessels.
Key Findings
The researchers systematically demonstrated that the mechanosensitive ion channels Piezo1 and Piezo2, distributed in lymphatic endothelial cells (LECs), act as key sensors for maintaining lymphatic homeostasis. These channels open in response to physical stimuli, rapidly allowing extracellular calcium ions (Ca2+) to enter the cell, thereby activating downstream signaling pathways.
Piezo1 serves as a hub that integrally controls major signaling pathways during lymphatic development. Specifically, it regulates lymphatic sprouting by coupling with the cell membrane calcium channel Orai1 and the Notch signaling pathway, and induces valve morphogenesis to prevent lymphatic reflux by interacting with the ANGPT/TIE/FOXO1 axis. Its association with the EPHB4/RASA1 signaling pathway, which is involved in vascular and lymphatic differentiation, was also demonstrated. The development of meningeal lymphatics, responsible for cerebrospinal fluid circulation and waste removal, was also found to depend on Piezo1-mediated calcium influx control.
Malfunction of this Piezo1 signaling system leads to significant pathological phenomena. Loss of channel function due to genetic abnormalities causes congenital lymphedema, which leads to systemic swelling, while excessive activation promotes lymphatic invasion and metastasis of cancer cells. Close associations with neurological disorders such as craniosynostosis and hydrocephalus were also confirmed. Disturbances in the Piezo2 channel, which transmits mechanical nociception, were identified as contributing to the chronic pain and sensory loss experienced by lymphedema patients, enhancing its value as a therapeutic target.
In terms of therapeutic strategies, multifaceted approaches have been proposed, including small-molecule agonists and inhibitors, CRISPR gene-editing technology, physical ultrasound stimulation, and drug-delivery nanoparticles. Strategies are being refined to artificially induce lymphangiogenesis using chemicals that regulate Piezo1 gating, or to block lymphatic expansion around tumor tissues.
Significance and Outlook
With the full picture of Piezo ion channels, which translate physical force into biochemical responses, coming to light, a structural turning point has been established for treating lymphatic dysfunction, previously classified as an intractable disease. This introduces a molecular-level alternative—targeted drug therapy—to the field of lymphedema treatment, which previously relied on physical symptomatic therapies such as surgical anastomosis or compression bandaging. The development of adjuvant therapies to block remote cancer metastasis by inhibiting lymphangiogenesis within the tumor microenvironment is also expected to accelerate.
The challenges ahead are clear. Since Piezo1 and Piezo2 are widely distributed in various organ tissues such as vascular endothelial cells, the heart, lungs, and bladder, there is a risk of cardiovascular side effects or organ dysfunction upon systemic administration. Precision delivery technologies that selectively deliver drugs to the target lymphatic vessels, supported by spatiotemporal on/off control technologies, are required. The combination of multiscale biomechanical modeling and patient-derived lymphatic organoid evaluation platforms is considered a key to reducing uncertainty in the preclinical stage and accelerating clinical entry.
In recent years, the role of mechanosensation in lymphatic system development, functional homeostasis, and disease progression has received increasing attention. As key mechanosensitive receptors in lymphatic endothelial cells, Piezo1/2 ion channels respond to biomechanical stimuli such as fluid shear stress and interstitial pressure, thereby regulating calcium influx and downstream signaling pathways. These channels play pivotal roles in physiological processes, including lymphatic network formation, valve development, and the maintenance of meningeal lymphatic function. This review systematically describes the structural features and dynamic mechanisms of Piezo1/2 channels, with a particular focus on their biological functions within the lymphatic system. Piezo1 integrates multiple signaling pathways, including the Orai1/Notch, ANGPT/TIE/FOXO1, and EPHB4/RASA1 signaling pathways, to regulate lymphatic sprouting, valve morphogenesis, and meningeal lymphatic development. Dysregulation of Piezo1 function has been demonstrated to be closely associated with congenital lymphoedema, tumor lymphatic metastasis, and neurological disorders such as hydrocephalus and craniosynostosis. In addition, the potential role of Piezo2 in the sensory impairments associated with lymphoedema warrants attention. With respect to therapeutic strategies, this review comprehensively summarizes approaches targeting Piezo1/2, including the development of small-molecule agonists/inhibitors, gene-editing technologies, physical modulation methods, and advanced drug delivery systems, as well as their research progress and clinical prospects. Despite persistent challenges such as insufficient tissue specificity and limited spatiotemporal precision, the integration of multiscale biomechanical models, organoid platforms, and multidisciplinary research strategies holds promise for translational breakthroughs in Piezo1/2 ion channel research, providing a new paradigm for precision therapy of lymphatic system disorders.
This research presents concrete possibilities for drug therapy for patients suffering from severe lymphedema following lymph node dissection for breast or gynecological cancers. Applying a nano-gel patch that locally releases Piezo1 activators to damaged lymphatic areas could promote lymphatic sprouting and valve reconstruction, facilitating the drainage of stagnant lymph fluid. Complex therapies integrating Piezo2 regulation technology can simultaneously alleviate tissue fibrosis and paresthesia caused by lymphatic occlusion. In the field of cancer treatment, it is expected that clinical protocols will be designed utilizing lymphatic-targeted anticancer delivery vehicles loaded with Piezo1 inhibitors to selectively block lymphatic expansion around tumors, thereby fundamentally blocking the pathway for lymph node metastasis.